Blood Pressure Control and Maintenance in a Prospective Cohort of Younger Veterans:

Roles of Sex, Race, Ethnicity, and Social Determinants of Health

SHORT TITLE: BLOOD PRESSURE CONTROL IN YOUNGER VETERANS

Allison E. Gaffey, PhD, FAHA^{a,b,c*}, Tiffany E. Chang, PhD, MPH^d, Cynthia A. Brandt, MD, MPH^{a,e}, Sally G. Haskell, MD^{a,f}, Sanket S. Dhruva, MD, MHS^{g,h}, Lori A. Bastian, MD, MPH^{a,f}, Allison Levine, PharmD, BCACP, BCGP,^a Melissa Skanderson, MSW^a, & Matthew M. Burg, PhD^{a,b,i}

^aVA Connecticut Healthcare System, West Haven, CT ^bDepartment of Internal Medicine (Cardiovascular Medicine), ^c ^dDepartment of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT ^eDepartment of Biostatistics, Yale School of Medicine ^fDepartment of Internal Medicine (General Medicine), Yale School of Medicine ^gSan Francisco Veterans Affairs Health Care System, San Francisco, CA ^hSection of Cardiology, Department of Medicine, UCSF School of Medicine ⁱDepartment of Anesthesiology, Yale School of Medicine

SOCIAL MEDIA HANDLES: @YaleMed, @YaleIMed, @YaleCardiology, @VAHSRD, @DrAllisonGaffey, @TiffanyEChang, @UCSFCardiology

***CORRESPONDENCE:**

Allison E. Gaffey, PhD Yale School of Medicine 333 Cedar Street, New Haven, CT 06510 Phone: 203-932-5711, ext.3332, Fax: 203-937-3884, allison.gaffey@yale.edu

Manuscript Words: 5776/6000, Abstract Words: 249/250 Tables: 5, Figures: 1

Abstract

Background: Proactive blood pressure (BP) management is particularly beneficial for younger Veterans, who have a greater prevalence and earlier onset of cardiovascular disease than non-Veterans. It is unknown what proportion of younger Veterans achieve and maintain BP control after hypertension onset and if BP control differs by demographics and social deprivation.

Methods: Electronic health records were merged from Veterans who enrolled in VA care 10/1/2001-9/30/2017 and met criteria for hypertension – first diagnosis or antihypertensive fill. BP control (140/90 mmHg), was estimated 1, 2, and 5 years post-hypertension documentation, and characterized by sex, race, and ethnicity. Adjusted logistic regressions assessed likelihood of BP control by these demographics and with the Social Deprivation Index (SDI).

Results: Overall, 17% patients met criteria for hypertension (n=198,367; 11% of women, median age 41). One year later, 59% of men and 65% of women achieved BP control. After adjustment, women had a 72% greater odds of BP control than men, with minimal change over 5 years. Black adults had a 22% lower odds of BP control than White adults. SDI did not significantly change these results.

Conclusions: In the largest study of hypertension in younger Veterans, 41% of men and 35% of women did not have BP control after 1 year, and BP control was consistently better for women through 5 years. Thus, the first year of hypertension management portends future, long-term BP control. As social deprivation did not affect BP control, the VA system may protect against disadvantages observed in the general U.S. population.

Keywords: hypertension; control; blood pressure; risk; Veterans; sex differences; race; social determinants of health

Non-standard Abbreviations and Acronyms

ACE-inhibitor, Angiotensin-converting enzyme inhibitors

- AHM, antihypertensive medication
- ARBs, angiotensin receptor blockers
- BMI, body mass index
- BP, blood pressure
- CI, confidence interval
- CVD, cardiovascular disease
- EHR, electronic health record

ICD-9-CM and 10, International Classification of Diseases, Ninth Revision, Clinical Modification and Tenth Revision

MST, military sexual trauma

NHANES, National Health and Nutrition Examination Survey

OR, odds ratio

- OSA, obstructive sleep apnea
- PTSD, posttraumatic stress disorder
- SDI, Social Deprivation Index
- SDoH, social determinants of health
- VA, Department of Veterans Affairs

INTRODUCTION

Men and women U.S. military Veterans show an earlier elevation in blood pressure (BP) and a greater risk of hypertension and cardiovascular disease (CVD) than non-Veterans.¹⁻⁵ Proactive, guideline-based BP management can mitigate the proximal impact of hypertension on cardiovascular health and later CVD risk,⁶ which could be particularly beneficial for younger Veterans – i.e., those discharged from military service post-9/11.⁷ In recent years BP control has decreased in the U.S.,⁸ a decline observed across all demographic groups.⁹ Over half of younger Veterans seek care through the Department of Veterans Affairs (VA),¹⁰ yet it is unknown how well BP is controlled among this group. As younger adults show lower hypertension awareness, treatment and control than older adults,¹¹ information concerning BP control in this at-risk, younger group of Veterans can dually inform hypertension management and improve CVD prevention.

The population of younger, post-9/11 Veterans is more demographically heterogeneous compared to those who served in earlier conflicts.^{12,13} By 2042, women will represent 20% of the Veteran population,¹⁰ and are more likely to use VA benefits than men.¹⁰ Furthermore, almost half of women Veterans are non-White.¹⁴ In the general population, non-Hispanic Black men and women show the greatest prevalence of hypertension.^{6,15} There are also notable variations in hypertension management and BP control by sex, race, and ethnicity.¹⁶ Given the high representation of women and members of racial and ethnic minorities, determining if BP control varies by demographic factors is necessary to support the cardiovascular healthcare needs of younger Veterans.

Social determinants of health (SDoH) – the conditions in which people are born, grow, work, live, and age – contribute to cardiovascular health, risk for hypertension, and CVD outcomes,^{17,18}

and may underlie intersectional differences in BP control.¹⁹ In the general population, those with a lower income, who live in under resourced neighborhoods, and who have less healthcare access, are less likely to have controlled BP.²⁰ As the VA system of care is designed to offset the adverse effects of many individual and systemic SDoH,²¹ those who receive care through the VA may experience a lower burden of social deprivation on BP management. With increasing recognition of the importance of SDoH, it is informative to explore if SDOH affect potential demographic differences in BP control.

This investigation used data from a nationwide, prospective cohort study of >1 million young and middle-aged Veterans who served in support of U.S. conflicts in Iraq and Afghanistan (post-9/11) and who enrolled in VA care to pursue four objectives. First, to determine the proportion of men and women who met criteria for hypertension based on a diagnosis or receipt of an antihypertensive medication (AHM). We hypothesized that women, particularly members of racial and ethnic minority groups, would be less likely to have a diagnosis of hypertension and AHM than their male counterparts. A second objective was to determine the proportion of patients who achieved BP control at 1, 2, and 5 years after the first evidence of hypertension. We hypothesized that rates of BP control would increase over time. A third objective was to determine if there are differences BP control based on sex, race, and ethnicity. It was hypothesized that a greater percentage of women would show BP control than men, and that White, non-Hispanic individuals would show better BP control than other racial and ethnic groups. The fourth, exploratory objective was to test if including a composite measure of SDoH would affect potential subgroup differences in BP control.

METHODS

Data Sources

Data used for these analyses are covered under a proprietary data use agreement with the Department of Veterans Affairs and are not available for distribution by the authors. Eligible men and women were identified from rosters maintained by the VA's Defense Manpower Data Center – Contingency Tracking System. We extracted patients' electronic health record (EHR) data from the national VA Corporate Data Warehouse. These data included vital sign and coded diagnostic and procedural data from all VA healthcare visits. The records were combined with additional administrative, pharmacy, and diagnostic data (based on International Classification of Diseases, Ninth Revision, Clinical Modification and Tenth Revision [ICD-9-CM and 10] codes and dates).

Study Population

The Women Veterans Cohort Study (WVCS) is a prospective investigation of all post-9/11 men and women Veterans (i.e., those who served during conflicts in Afghanistan and Iraq, including Operations Enduring Freedom, Iraqi Freedom, and New Dawn), who were discharged from service as of October 1, 2001-September 30, 2017, and whose first VA outpatient medical visit occurred after their last date of service and before September 30, 2017. The original cohort was restricted to those with a diagnosis of hypertension, defined as i) an ICD-9 or 10 code recorded during at least 2 outpatient or 1 inpatient encounter, or ; ii) at least 1 AHM prescription filled at a VA Pharmacy. In addition to meeting criteria for hypertension, eligible patients were required to have at least two qualifying BP measurements taken after their first date of VA care and before the end of the 5-year follow-up period. Furthermore, to explore potential differences in BP control by SDoH categories, patients were excluded from the analysis if they had a missing or invalid 5-digit residential zip code, or if their zip code corresponded to Puerto Rico, since linked

SDoH data was unavailable (n=7,311). These criteria resulted in a final analytic sample of 198,367 men and women.

Primary and Secondary Predictors: Sex, Race, and Ethnicity

Patients' sex (men, women), race and ethnicity (non-Hispanic White, non-Hispanic Black, Hispanic, Asian, Other race) were extracted from the Department of Defense roster files. Sex was the primary predictor, while race and ethnicity data were combined as the secondary predictor.

Exploratory Predictor: Social Deprivation Index

An index of SDoH was used to explore if inclusion influenced associations between the demographics and likelihood of BP control. The Social Deprivation Index (SDI) is a composite measure of a geographic area's estimated deprivation level that is derived from 7 measures in the American Community Survey: the percentage of adults living in poverty; with <12 years education; residing in a single-parent household, a rented housing unit, or an overcrowded housing unit; households without a car; and unemployed individuals aged <65 years.²² Analyses were based on publicly available 2015 data (https://www.graham-center.org/maps-data-tools/social-deprivation-index.html). Area-level SDI scores were linked with patients' residential zip codes. Scores range from 1 to 100, with higher scores indicating greater disadvantage.

Outcome: BP control

BP control was assessed 1, 2, and 5 years after a patient first met criteria for hypertension. BP results were limited to outpatient assessments to avoid potential transient changes from acute hospitalizations.²³ Qualifying BP measurements included those within biologically plausible ranges (systolic 70-240 mmHg; diastolic 35-140 mmHg²⁴). To address multiple BP

measurements within a 5-minute period: a) if measurements were identical (i.e., duplicate systolic or diastolic values), then one set was deleted; b) if there were 2 unique measurements within a 5-minute period, the means of each systolic and diastolic measurements were used to represent a single BP measurement; c) if there were >2 unique measurements within one 5-minute time window, the first BP measurement was dropped and the mean of the remaining values was used.²³ BP control was assessed using the last 2 outpatient clinic BP measurements within 1, 2, and 5 years of the qualifying hypertension diagnosis date, and was defined by the last 2 systolic and diastolic measurements. As the duration of follow-up was generally before 2017 updates to the clinical practice guidelines for BP management,^{25,26} BP control was evaluated using a threshold of <140/90 mmHg.

Covariates

Covariates were chosen *a priori* and measured at baseline or during the first evidence of diagnosis across follow-up. These included demographics: age (<40 vs \geq 40 years) and marital status (married vs not married); behavioral/lifestyle factors: smoking status (current, past, never), body mass index (BMI; categories of underweight/normal, overweight, and obese [reference]), and history of an alcohol or substance use disorder (ever diagnosed vs. never [reference]); history of MST²⁷ and other clinical risk factors (ever diagnosed vs. never [reference]): posttraumatic stress disorder (PTSD), obstructive sleep apnea (OSA), Type 1 or 2 diabetes, dyslipidemia; and the number of comorbidities using a modified version of the Charlson Comorbidity Index (i.e., this version did not include leukemia or lymphoma in the weights).²⁸ Lastly, a healthcare utilization variable was created based on the number of primary care visits completed within first 2 years.²⁹ Patients were also characterized by education, rurality of residence, the availability of additional, non-VA health insurance at baseline, BP category at

baseline (<120/80 mmHg, 120-129/<80 mmHg, 130-139/80-89 mmHg, 140-159/90-99 mmHg, or \geq 160/100 mmHg^{26,30}), and if available, by the first AHM prescribed. Finally, SDI quartiles were included (ranging from Quartile 1=least disadvantaged to Quartile 4=most disadvantaged). As education and rurality are included in the calculation of SDI composites, these variables were not examined as independent covariates.

Statistical analysis

Statistical analyses were conducted using SAS version 9.4 (Cary, NC) with p<0.05 as the statistical significance threshold. First, descriptive and bivariate statistics were used to summarize the data and to determine differences in demographic and clinical factors with BP control at 1, 2, and 5 years. These tests were conducted by sex, race, and ethnicity subgroups. Next, random intercept, multilevel logistic regression models were conducted using the GLIMMIX procedure to assess the associations between sex, race and ethnicity, and BP control. The odds of BP control were modeled separately for 1, 2, and 5 years. Since the primary predictors were sex, race, and ethnicity, the initial, unadjusted models only included the independent associations of sex or race/ethnicity on BP control (Model 1). Next, the logistic regression models included stepwise adjustment for: other demographics (Model 2), behavioral/lifestyle factors (Model 3), and clinical risk factors (Model 4). In additional models, we tested the two-way interactions of sex and race on BP control. Finally, exploratory analyses were also conducted to include SDI.

RESULTS

Demographic data were available from 1,177,204 patients (12% of whom were women [n=146,091] Figure 1). Among that group, 922,543 patients (13% women [n=115,402]) had at least 1 BP measurement in an outpatient setting. As seen in Table 1, 198,367 unique patients met

at least one criterion for hypertension – a diagnosis or AHM fill (11% of whom were women [n=20,814]). Of that group, 50% of patients had both a hypertension diagnosis and an AHM fill, 18% had only a diagnosis, and 33% had a prescription for an AHM but no diagnosis of hypertension. Of those who met criteria for hypertension, more men than women had both documentation of a hypertension diagnosis and an AHM prescription (51% vs. 38%). Among men and women, those who identified as non-Hispanic Black were more likely to have a hypertension diagnosis and an associated AHM fill (61% and 49%) than same-sex men and women in other subgroups.

Table 2 presents demographic, behavioral, and clinical characteristics of patients with hypertension, by sex. At baseline, the median ages of men and women were 41 and 42 years. Overall, a significantly greater percentage of women were non-White, unmarried, and lived in an urban locale compared to men. When examining behavioral factors, fewer women than men had ever smoked, were categorized as obese, or ever had a diagnosis of alcohol use disorder or substance use disorder. In relation to men, a greater percentage of women had a documented history of MST, but significantly fewer women than men had a diagnosis of PTSD, diabetes, dyslipidemia, or OSA. Women had slightly fewer AHM fills across the duration of follow-up and attended significantly more primary care visits compared to men. The average follow-up time was similar by sex – over 3 years for each group. Slightly more women vs men were in the most disadvantaged SDI quartile (29% vs 25%).

Table 3 presents characteristics of men and women who met criteria for hypertension by sex, race, and ethnicity. Of the men who met criteria for hypertension, White, Hispanic, and Otheridentified groups had the highest percentage of individuals who were under age 40 and unmarried. In all racial and ethnic groups, more men lived in urban vs. rural settings. Over half

of White, non-Hispanic men were current smokers, which was a significantly greater prevalence than observed in other groups. White men were less likely to have a diagnosis of diabetes or OSA compared to the other groups. Hispanic men showed the greatest prevalence of PTSD, depression, and OSA compared to others. Based on BP assessed at baseline, the highest percentage of men in each race and ethnicity group were categorized as 130-139/80-80mmHg (37-40%) and each race and ethnicity group were similarly prescribed an angiotensin converting enzyme inhibitor (ACE-inhibitor) as their first AHM.

When examining the sample of women with hypertension, there was a similar age distribution between White, Hispanic, and Other subgroups, although a greater proportion of Black and Asian women were older than 40. In each subgroup more women had a high school education or less and lived in an urban vs. rural locale. Compared to other subgroups, White women were more likely to currently smoke and to have an anxiety diagnosis but were less likely to be diagnosed with diabetes. In contrast, women who identified as Black, and Hispanic, and Other race showed the highest prevalence of PTSD and depression among the groups. For about 1 in 3 women from each group, baseline BP was in the range of 130-139/80-80mmHg. All groups of women were typically prescribed an ACE-inhibitor first, except for Black women who were more likely to be prescribed a calcium channel blocker.

As depicted in Table 4, within one year of meeting criteria for hypertension, 55% of men and 69% of women had controlled BP. Men who were \geq 40 years, Asian or Hispanic, married, with more than a high school education, insurance, no history of substance use disorder, and a normal/underweight BMI, had significantly better BP control than men in comparison groups. Among women, a greater proportion with controlled BP were <40 years old, White, or Hispanic. Two years after the onset of hypertension, approximately 54% of men and 67% of women had

controlled BP. For men, BP control was again better for those who were younger, married, more educated, and without substance use disorders or PTSD. Among women, BP control was significantly better for those who were younger, identified as White or Hispanic, and without a substance use history than women in comparison groups. At five years beyond initial hypertension documentation, 53% of men and 66% of women demonstrated BP control. Among men, those who were younger, Asian, married, educated, without a substance use disorder history, and without an OSA diagnosis showed better BP control than men in reference groups. Similarly, women who were younger, White or Hispanic, and in the lowest SDI quartile showed significantly better BP control compared to women in reference groups.

In unadjusted models of BP control at year 1, women had a 90% greater likelihood of BP control than men. Results from the adjusted multivariable tests of Years 1, 2, and 5 are depicted in Table 5. After multivariable adjustment for demographics, behavioral factors, and clinical factors, women still showed a 66% greater odds of BP control than men (95% CI: 1.59-1.63). Younger age, Hispanic ethnicity, and having a diagnosis of PTSD, were associated with increased odds of controlled BP at 1 year after meeting criteria for hypertension. Yet, Black, Asian, and Other racial groups, being unmarried, a current smoker, overweight or obese, and a history of substance abuse were associated with a lower likelihood of controlled BP. Finally, the interaction between sex and race/ethnicity was significant (p=0.006). Compared to White men, both Black (OR: 0.81 [95% CI: 0.78-0.84]) and Other-identified groups of men showed a significantly lower likelihood of BP control (OR: 0.88 [95% CI: 0.81-0.95]). Similarly, compared to White women, the likelihood of BP control was lower for women who identified as Black (OR: 0.67 [95% CI: 0.61-0.74]), Asian (OR: 0.65 [95% CI: 0.46-0.90]), and women who were members of Other racial groups (OR: 0.76 [95% CI: 0.60-0.96]).

At Year 2, women had an 83% greater likelihood of BP control than men, an association that decreased to 62% in the fully adjusted model (95% CI: 1.54-171). Younger age and greater primary care utilization were also associated with a greater odds of BP control. Black and Other races, being unmarried, current smoking, overweight or obesity, and substance use were associated with the likelihood of controlled BP. The Sex*Race/Ethnicity interaction was again significant at this timepoint (p<0.001), with other patterns similar to those observed in Year 1. Finally, at Year 5 women showed an 80% greater, unadjusted odds of BP control than men. After adjustment, women showed a 60% greater likelihood of BP control vs. men (95% CI: 1.53-1.69). As observed with earlier timepoints, younger age, a PTSD diagnosis, and primary care utilization were each associated with BP control. Conversely, patients who were Black and Other race, unmarried, current smokers, overweight or obese and with a substance use history had lower BP control. The Sex*Race interaction was again significant (p<0.001), with other associations like those observed in Year 2 and 5.

Finally, SDI was introduced in exploratory analyses to determine if social deprivation would attenuate effects of sex, race, or ethnicity on BP control. Overall, at Year 1, patients who resided in the most disadvantaged areas showed a 5% lower odds of BP control than the least disadvantaged group (Quartile 4 vs. Quartile 1; 95% CI: 0.91-0.99). This association remained in Year 2 (OR 0.94 [95% CI: 0.91-0.98]) and Year 5 (OR 0.95 [95% CI: 0.91-0.99]). Still, the previous associations of sex, race, and ethnicity and likelihood of BP control were maintained each year. When stratifying the SDI analyses by demographic subgroups, the effect of SDI on BP control only remained for select groups. Among men at Year 1, those who identified as Black and belonged to most disadvantaged SDI group (Quartile 4) had an 11% lower likelihood of BP

control than those in the most advantaged group (Quartile 1; 95% CI 0.81-0.99). This association was maintained at the Year 2 (OR 0.89 [95% CI: 0.81-0.98]) and Year 5 timepoints (OR 0.88 [95% CI: 0.80-0.97]). Men who identified as Other and in SDI Quartile 2 also had a 23% lower odds of BP control than those in Quartile 1 (95% CI: 0.61-0.96). Finally, Black women in SDI Quartile 3 showed a 21% lower likelihood of BP control at the Year 2 and 5 timepoints (both 95% CI: 0.61-0.96).

DISCUSSION

In this 16-year, prospective, nationwide cohort study of younger adults, 17% of patients met criteria for hypertension. One year after meeting initial criteria for hypertension, 45% of men and 31% of women had not achieved BP control. After adjustment for other demographic, behavioral, and clinical variables, within one year, BP control was 66% more likely for women than men, and this difference was consistently observed up to five years later. Yet contrary to our hypothesis, the proportions of men and women who achieved BP control decreased across the 2and 5-year timepoints, rather than increasing. In addition to differences by sex, patients who were younger and with a PTSD diagnosis were more likely to have BP control while those who were older, unmarried, current smokers, obese, and with a substance use disorder were all less likely to demonstrate BP control, factors that were similar for men and women, and over time. The sex-specific prevalence of BP control also differed by race and ethnicity. Among men and women, adults who identified as Black and Other race showed worse BP control than their White counterparts. However, women who identified as Asian also had significantly worse BP control than patients who were same-sex and White. Altogether, these data show that disaggregating the population of patients with hypertension by sex, race, and ethnicity is important to determine which subgroups may require more clinical and social support to achieve BP control.

The present study revealed differences between men and women in both the identification of hypertension and in subsequent BP control. Per 2017-2018 data from the U.S. Centers for Disease Control and the National Health and Nutrition Examination Survey (NHANES), the prevalence of hypertension among younger and middle-aged adults is 31%-59% for men and 13%-50% for women.³¹ Despite patients' greater risk for later CVD,¹⁻⁵ in the present cohort, considerably fewer adults met criteria for hypertension than expected – 18% of men and 15% of women. These differences may be due to a lingering healthy soldier effect in the initial years following service,³² which has been estimated to lower health-related risk by 10%-25%,³³ to underdiagnosis of hypertension among this complex patient population, and to slightly different inclusion criteria as NHANES participants can also meet criteria for hypertension based on BP readings. To conservatively estimate the prevalence of hypertension in the present study, and given greater multimorbidity observed among Veterans, BP was not used as a sole inclusion criterion. Variability in hypertension documentation was also observed. One-third of adults in VA care were prescribed an AHM but did not have a documented diagnosis of hypertension. As hypothesized, significantly fewer men than women -31% versus 49% – were missing a hypertension diagnosis. Contrary to expectation, a higher percentage of Black men and women were each more likely to meet both hypertension criteria than same-sex individuals who were characterized as other race and ethnicity groups. Perhaps those without medications are less aware of their hypertension status, or among those without a documented hypertension diagnosis, clinicians may be less attentive to BP control, both questions that could be pursued in future investigations.

Characterizing BP control by sex is important in light of the growing evidence that men and women differ in associations from BP to CVD outcomes.³⁴ While there are known sex

differences in the receipt of diagnosis and guideline-directed management of established CVD among Veterans served by the VA,³⁵ the degree to which BP control differs by sex is relatively unexplored among younger Veterans, for whom early BP control can have the greatest effect for later morbidity and mortality. Within one year of meeting study criteria for hypertension, 55% of men and 69% of women had controlled BP, similar that were similar to NHANES data from the general population.^{25,36} Confirming our hypothesis, women were 66% more likely to achieve initial BP control than men, and maintained this greater likelihood of BP control for five years. In contrast, NHANES data showed little difference in hypertension control rates by sex.⁸ Other, past investigations of sex differences in BP control yielded conflicting results, with some showing that men or women each have better BP control than adults of a comparable age, or that there is no difference by sex, with variability in these results based on age, race, and ethnicity.^{16,25,37} Sex differences in hypertension management could begin with the patient's knowledge about their health. Compared to younger men, same-aged women are 35% more likely to be aware of their hypertension,³⁸ a difference that may be attributable to women's greater healthcare utilization, and may explain results for the present study. Among Veterans specifically, younger women utilize VA care more frequently than their male counterparts,²⁹ providing more opportunities for BP monitoring and management. In consideration of these converging lines of evidence, sex-specific approaches to BP management may be helpful, but have not yet been developed and tested.^{39,40}

Upon examining sex, race, and ethnicity concurrently, as hypothesized, a greater proportion of White adults had BP control than Blacks at each timepoint. White and Black women also each showed significantly better BP control than their same-race male counterparts, associations that persisted through five years. When comparing BP control within sex, Black men and women

each had worse BP control than same-sex individuals who identified as White. Thus, the present findings provide two important extensions of past data among Veterans⁴¹⁻⁴³ – examining sex by race/ethnicity interactions and comparing racial and ethnic subgroups within men and women, respectively. In the present results, our study replicates some of the racial disparities observed in NHANES and other large datasets.⁸ Given that the VA system is designed to offer uniform care to all Veterans, disparities in the outcomes of treatment may occur due to clinician judgment and bias, and the quality of care at facilities more frequented by racial and ethnic minorities groups.^{44,45} It is also possible that subgroup differences in BP control are due to racial differences in trust, awareness, adherence, and health beliefs,⁹ which should also be investigated among younger Veterans, particularly women.⁴⁵

SDoH can influence vulnerability to hypertension, access to treatment, and long-term BP management,¹⁷ particularly among women.⁴⁶ Yet, adding the SDI as a proxy of SDoH did not significantly alter associations with BP control. Overall, patients who were categorized as most disadvantaged showed only a 5% lower likelihood of BP control compared to the least disadvantaged group. However, in adjusted analyses stratified by demographic subgroups, effects of SDI were specific to non-Hispanic Black adults only, particularly men. The VA is the largest healthcare system in the U.S. and is designed to provide a uniform standard of care to Veterans that supersedes social disadvantages, which could explain why inclusion of SDI did not greatly influence the likelihood of BP control by sex, race, or ethnicity. Still, Black patients with hypertension and who show the greatest social deprivation also have the greatest difficulty with BP control. Among Veterans receiving VA care, SDoH-related disparities may be mostly encapsulated by sex, race, and ethnicity, as in these analyses, then by other variables. Another recent retrospective cohort study of Veterans with heart failure found no meaningful differences

in treatment receipt between those who lived in rural or urban locations.⁴⁷ However, as SDI was a composite index, it is worth investigating if specific social deprivation variables – e.g., unemployment, living conditions – are more predictive of BP control among younger Veterans, and if associations are specific to certain subgroups or vary by disadvantage level.

This research improves our knowledge of VA-wide efforts to manage BP among younger Veterans, potential inequities in clinical care for hypertension, and the effect of these two major events on cardiovascular risk management among younger Veterans. In support of the observed disparities in the provision of AHM, among a sample of adults with similar BP, women were less likely to receive AHM at all.⁴⁸ In terms of first-line therapy for reproductive-age women, when AHM are prescribed, a lower percentage of women were prescribed certain medications than men (i.e., ACE inhibitors and angiotensin receptor blockers [ARBs]), due to potential for teratogenicity among women of reproductive age,⁴⁹ but these medications were still prescribed to over 20% of women, suggesting a lower quality of care when managing BP. Overall, sparse data indicate that women respond better to diuretics, ACE inhibitors and beta-blockers,⁵⁰ but those studies were based on other samples and there is little evidence concerning the comparative effectiveness of AHM in younger women. Improving BP control among young and middle-aged adults requires improved implementation of the existing guidelines – appropriate measurement of BP during office visits, and tools for home BP measurement, special consideration for additional changes needed by those with a history of uncontrolled hypertension, or with a past hypertensive disorder of pregnancy or during birth – including earlier encouragement of proactive lifestyle interventions and pursuit of pharmacologic options.⁵¹ Investigating the processes of BP assessment in the VA, such as alignment with BP management guidelines in the first year of care or the frequency with which home BP monitoring is used to verify BP assessed

in clinic,²⁶ will be valuable to determine how best to help younger men and women Veterans with hypertension and uncontrolled BP in the first year, and then over time.

Strengths of this investigation include accounting for hypertension among all men and women post-9/11 Veterans receiving VA care, and across a follow-up period of 16 years. The characteristics of this cohort also offered a singular opportunity to examine the specific effects of sex, race, and ethnicity, and multiple risk factors for hypertension and CVD, on BP control. Furthermore, hypertension was rigorously defined based on two mutually inclusive criteria – EHR diagnosis and AHM use. Finally, by limiting the sample to those with a documented zip code, it was possible to explore if demographics or SDoH were the most influential predictors of BP control.

The limitations of this investigation should also be enumerated. First, as the sample consisted of only post-9/11 Veterans who sought VA care, the results may not be generalizable to former military servicemembers from other eras, men and women who do not receive care through the VA, or to adults in the general population. Second, as this was a prospective cohort study involving EHR data, there is a risk for misclassification bias, selection bias, and missing data. For example, hypertension is also likely underdiagnosed, including among younger Veterans and those who are women, and to ensure our estimates were conservation we did not include patients based on BP readings from the EHR. Third, it was not possible to control for all aspects of lifestyle and behavioral factors or medication adherence in this investigation. Future investigations are required to better account for physical activity, diet, sleep duration, and psychosocial stress, particularly as those factors show differential associations by sex, race, ethnicity, and SDoH. Fourth, clinic BP measurement does not always reflect BP patterns indexed in non-clinical settings. Ambulatory BP monitoring or home BP monitoring are recommended to

confirm a diagnosis of hypertension and monitoring BP control but was not used in these data.^{26,30} Fifth, we did not examine demographic differences in BP control by type of AHM used or among those taking monotherapy vs combination therapy, which was beyond the scope of the present analyses and will be a valuable future investigation.⁵² Sixth, patients could have received care outside of the VA, including management of hypertension. Relatedly, exploring differences in BP assessment and management by these groups is a vital next step.

Perspectives:

BP control is a crucial aspect of CVD risk management. In this cohort of younger and middleaged Veterans receiving care through the VA, over half of patients demonstrated BP control in the first year after meeting criteria for hypertension, patterns that persisted through two and five years later. At each timepoint, women and White, non-Hispanic patients were more likely to show BP control than men and patients who identified as non-White, indicating that BP control warrants greater focus for male and Black Veterans. Relatively stable rates of BP control over the subsequent five years suggests that the first year of hypertension care is crucial for all. Finally, social deprivation did not significantly alter these associations, suggesting that the VA system may protect against some of the social inequity that is observed in the U.S. general population. Improving the identification of hypertension and expeditious, initial BP control in younger men and women should be a priority for VA and non-VA providers alike.

Novelty and Relevance:

- What Is New?
 - This is the largest prospective cohort study of younger men and women Veterans with a focus on determining the prevalence of hypertension and individual differences in blood pressure (BP) control.
 - 2. Unlike many previous examinations of BP control in younger adults and Veterans, data were based on electronic health records rather than self-report of hypertension and related BP control.
 - Following the cohort up to 5 years after they met criteria for hypertension allowed us to determine how BP control may change over time, and to identify individual differences in patterns of BP control, including exploring the role of social deprivation.
- What Is Relevant?
 - More men than women had both documentation of a hypertension diagnosis and an antihypertensive prescription (51% vs. 38%). By race and ethnicity, a greater proportion of Black men and women had both a hypertension diagnosis and an antihypertensive prescription and members of other race and ethnic groups.
 - 2. Within one year of meeting criteria for hypertension, about 1 in 2 men and 2 of 3 women had controlled BP, but these proportions decreased slightly over the next 5 years. Non-Hispanic, White patients had the highest rates of BP control at each timepoint, while Black adults and Asian women had the lowest BP control at 1 year. This distinction persisted over time for Black patients.

- Patients with the greatest social deprivation showed a 5% lower likelihood of BP control across 5 years, and Black men and women with greater social deprivation had the lowest odds of BP control.
- Clinical/Pathophysiological Implications?
 - Closely monitoring BP control for the first year should be sufficient for most patients with hypertension, but it is likely that regular, intensive BP management should extend through 5 years and beyond.
 - Younger patients who are Black, and Asian women, may especially benefit from additional BP management in the first year, and certain disadvantaged groups likely require greater, regular support to achieve BP control over time.

Acknowledgements: We would like to thank all the Veterans for their service and contributions to this investigation. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States Government.

Sources of Funding: Dr. Gaffey's effort was supported by a grant from the National Heart,

Lung, and Blood Institute of the National Institutes of Health (K23HL168233). Dr. Chang's

effort was supported by an American Heart Association Predoctoral Fellowship

(#23PRE1018200/2023-2024). Dr. Dhruva's effort was supported by a grant from the Veterans

Affairs Health Services Research & Development (11K2HX003357). Dr. Dhruva receives

funding from the Department of Veterans Affairs and Arnold Ventures.

Disclosures: Dr. Dhruva also reported serving on the Institute for Clinical and Economic Review California Technology Assessment Forum and Medicare Evidence Development & Coverage Advisory Committee. The other authors declare that they have no known competing financial interests or personal relationships that could have influenced the work reported in this manuscript.

Table 1. Percentage of patients who met criteria for hypertension, by sex, race, and ethnicity group (n=198,367).

	Total Total Hispanic									Wor	nen (<i>n</i> =20,8	14)	
	Total	Total			Hispanic		NH Other	Total	NH White	NH Black	Hispanic	NH Asian	NH Other
AHM fill	64,873	54,770	37,917	7,935	5,948	1,110	1,860	10,103	5,347	3,044	1,057	203	452
only	(32.7)	(30.9)	(34.0)	(20.7)	(34.3)	(27.2)	(29.8)	(48.5)	(59.5)	(34.4)	(60.9)	(49.3)	(55.0)
Hypertension diagnosis code only	34,608 (17.5)	31,784 (17.9)	19,907 (17.9)	7,193 (18.7)	2,890 (16.7)	710 (17.4)	1,084 (17.4)	2,824 (13.6)	989 (11.0)	1,511 (17.1)	181 (10.4)	58 (14.1)	85 (10.3)
AHM and hypertension diagnosis	98,886 (49.9)	90,999 (51.3)	53,663 (48.1)	23,293 (60.6)	8,484 (49.0)	2,256 (55.4)	3,303 (52.9)	7,887 (37.9)	256 (29.5)	4,297 (48.5)	498 (28.7)	151 (3.7)	285 (34.7)

Abbreviations: AHM, antihypertensive medication; HTN, hypertension; NH, non-Hispanic

	Men	Women	
	(<i>n</i> =177,553)	(<i>n</i> =20,814)	P *
Demographics			
	41.0	41.7	.0.001
Age, y (median)	(32.0,47.7)	(33.2,48.1)	< 0.001
Age (years)			< 0.001
<40	111,998 (63.1)	14,829 (71.3)	
40+	65,555 (36.9)	5,985 (28.8)	
Race and ethnicity			< 0.001
NH White	111,487 (62.8)	8,892 (43.2)	
NH Black	38,421 (21.6)	8,852 (42.5)	
Hispanic	17,322 (9.8)	1,736 (8.3)	
NH Asian	4,076 (2.3)	412 (2.0)	
NH Other	6,247 (3.5)	822 (4.0)	
Marital status			< 0.001
Not married	74,239 (41.8)	12,493 (60.1)	
Married	103,245 (58.2)	8,294 (39.9)	
Education			< 0.001
>HS	38,748 (21.8)	5,979 (28.7)	
<=HS	138,779 (78.2)	14,833 (71.3)	
Rurality of residence			< 0.001
Urban	123,166 (69.4)	16,242 (78.0)	
Rural	54,385 (30.6)	4,572 (22.0)	
Additional health insurance		, , , , , ,	< 0.001
No	82,835 (56.3)	9,785 (59.2)	
Yes	64,384 (43.7)	6,758 (40.9)	
Behavioral/lifestyle factors			
Smoking status			< 0.001
Never smoker	68,437 (38.7)	11,715 (56.5)	
Current	82,465 (46.6)	6,660 (32.1)	
Past	25,957 (14.7)	2,353 (11.4)	
BMI	20,007 (11.17)	_,	< 0.001
Normal/underweight	23,521 (13.3)	6,262 (30.1)	\0.001
Overweight	<u>23,321 (13.3)</u> 66,356 (37.4)	7,261 (34.9)	
Obese			
	87,676 (49.4)	7,291 (35.0)	<0.001
Alcohol or drug use disorder (ever)	104 210 (20 0)	12 5 47 (70 0)	< 0.001
No Voz	104,319 (68.8)	13,547 (79.2)	
Yes	47,313 (31.2)	3,568 (20.9)	
Clinical factors			0.001
Military sexual trauma history			< 0.001

Table 2. Demo	graphic and	l military s	service cha	racteristics,	presented by	y sex $(n=198,367)$.

ioi use u	nder a CCO license.		
No	146,735 (97.7)	11,342 (66.7)	
Yes	3,502 (2.3)	5,670 (33.3)	
PTSD			< 0.001
No	55,211 (36.4)	6,575 (38.4)	
Yes	96,421 (63.6)	10,540 (61.6)	
MDD			< 0.001
No	85,990 (56.7)	6,736 (39.4)	
Yes	65,642 (43.3)	10,379 (60.6)	
GAD			< 0.001
No	135,320 (89.2)	14,056 (82.1)	
Yes	16,312 (10.8)	3,059 (17.9)	
Diabetes			< 0.001
No	118,252 (78.0)	14,247 (83.2)	
Yes	33,380 (22.0)	2,868 (16.8)	
Dyslipidemia			< 0.001
No	84,051 (47.3)	13,458 (64.7)	
Yes	93,502 (52.7)	7,356 (35.3)	
OSA			< 0.001
No	89,627 (59.1)	12,702 (74.2)	
Yes	62,005 (40.9)	4,413 (25.8)	
Number of comorbidities			< 0.001
0	44,179 (29.1)	3,913 (22.9)	
1	53,610 (35.4)	6,935 (40.5)	
2	25,694 (16.9)	3,472 (20.3)	
3	12,104 (8.0)	1,322 (7.7)	
4	7,321 (4.8)	717 (4.2)	
5+	8,724 (5.8)	756 (4.4)	
Social deprivation			
SDI			< 0.001
Quartile 1 (least disadvantaged)	44,930 (25.3)	4,591 (22.1)	
Quartile 2	43,486 (24.5)	5,016 (24.1)	
Quartile 3	44,764 (25.2)	5,282 (25.4)	
Quartile 4 (most disadvantaged)	44,373 (25.0)	5,925 (28.5)	
Healthcare utilization			
# of primary care visits within 2			
years of cohort entry, median (IQR)	3 (2,6)	4 (2,8)	< 0.001
Follow-up period for analysis,			
median (IQR)	3.5 (1.6,4.4)	3.6 (1.7,4.5)	< 0.001
Baseline BP category†			< 0.001
<120/80 mmHg	25,564 (14.4)	6,305 (30.3)	
120-129/<80 mmHg	20,700 (11.7)	2,580 (12.4)	
130-139/80-89 mmHg	69,089 (38.9)	7,055 (33.9)	

140-159/90-99 mmHg	48,580 (27.4)	3,812 (18.3)	
≥160/100 mmHg	13,620 (7.7)	1,062 (5.1)	
Count of AHM fills, median (IQR)	7 (3,16)	5 (2,12)	< 0.001
First AHM category prescribed			< 0.001
ACE inhibitors	54,822 (30.9)	3,636 (17.5)	
ARBs	6,166 (3.5)	589 (2.8)	
Beta blockers	31,153 (17.6)	6,368 (30.6)	
Calcium channel blocker	29,083 (16.4)	3,801 (18.3)	
Thiazide diuretic	24,252 (13.7)	3,551 (17.1)	
Missing (hypertension diagnosis			
code only)	32,077 (18.1)	2,869 (13.8)	

Abbreviations: ACE inhibitors, angiotensin-converting enzyme inhibitors; AHM, antihypertensive medication; ARBs, angiotensin receptor blockers; BP, blood pressure; BMI, body mass index; EHR, electronic health record; GAD, generalized anxiety disorder; MDD, major depressive disorder; MST, military sexual trauma; NH, non-Hispanic; OSA, obstructive sleep apnea; PTSD, posttraumatic stress disorder; SDI, Social Deprivation Index

Data are presented as N (%). All other data are presented as median (Q1, Q3). *P-value tests differences across all sex, race, and ethnicity groups using chi-square test for categorical variables, Kruskal-Wallis test for continuous non-normally distributed variables. †If an individual was in 2 different categories based on systolic and diastolic BP, they were placed in the higher BP category.

	Men (<i>n</i> =177	,553)					Women (<i>n</i> =20,814)						
	NH White men n=111,487 62.8%	NH Black men <i>n</i> =38,42 1 21.6%	Hispanic men <i>n</i> =17,322 9.8%	NH Asian men n=4,076 2.3%	NH Other race men <i>n</i> =6,247 3.5%	Р	NH White women <i>n</i> =8,992 43.2%	NH Black women n=8,852 42.5%	Hispanic women <i>n</i> =1,736 8.3%	NH Asian women n=412; 2.0%	NH Other race women <i>n</i> =822 4.0%	P	
Age, y	40.1	42.5	39.3	44.3	40.4		41.3	42.0	39.3	44.3	41.1		
(median)	(31,48)	(35,48)	(31,47)	(35,50)	(32,47)	< 0.001	(32,49)	(34,48)	(31,48)	(37,51)	(33,48)	< 0.001	
Age (years)					· · · /	< 0.001						< 0.001	
	74,443	19,554	11,884	2,149	3,968		7,036	5,485	1,410	276	622		
<40	(66.8)	(50.9)	(68.6)	(52.7)	(63.5)		(78.3)	(62.0)	(81.2)	(67.0)	(75.7)		
	37,044	18,867	5,438	1,927	2,279		1,956	3,367	326	136	200		
≥40	(33.2)	(49.1)	(31.4)	(47.3)	(36.5)		(21.8)	(38.0)	(18.8)	(33.0)	(24.3)		
Marital													
status						< 0.001						< 0.001	
Not	48,686	14,255	7,131	1,517	2,650		5,380	5,446	996	200	471		
married	(43.7)	(37.1)	(41.2)	(37.2)	(42.4)		(59.8)	(61.5)	(57.4)	(48.5)	(57.3)		
	62,764	24,142	10,185	2,558	3,596		3,601	3,395	738	210	350		
Married	(56.3)	(62.9)	(58.8)	(62.8)	(57.6)		(40.1)	(38.4)	(42.5)	(51.0)	(42.6)		
Education						< 0.001						< 0.001	
	25,596	7,514	3,186	1,188	1,264		2,649	2,593	377	162	198		
>HS	(23.0)	(19.6)	(18.4)	(29.2)	(20.2)		(29.5)	(29.3)	(21.7)	(39.3)	(24.1)		
	85,877	30,906	14,129	2,887	4,980		6,343	6,258	1,358	250	624		
≤HS	(77.0)	(80.4)	(81.6)	(70.8)	(79.8)		(70.5)	(70.7)	(78.3)	(60.7)	(75.9)		
Rurality of					·								
residence						< 0.001						< 0.001	
	68,787	31,413	14,773	3,775	4,418		6,113	7,594	1,515	373	647		
Urban	(61.7)	(81.8)	(85.3)	(92.6)	(70.7)		(68.0)	(85.8)	(87.3)	(90.5)	(78.7)		
	42,699	7,007	2,549	301	1,829		2,879	1,258	221	39	175		
Rural	(38.3)	(18.2)	(14.7)	(7.4)	(29.3)		(32.0)	(14.2)	(12.7)	(9.5)	(21.3)		
Additional health													
insurance						< 0.001						0.0539	

Table 3. Demographic, behavioral, and clinical characteristics, presented by sex, race, and ethnicity (n=198,367).

	52,456	17,144	8,560	1,637	3,038		4,363	3,957	883	167	415	
No	(56.0)	(55.9)	(59.0)	(51.3)	(58.6)		(60.4)	(57.0)	(62.5)	(54.4)	(62.7)	
	41,206	13,535	5,940	1,557	2,146		2,856	2,985	530	140	247	
Yes	(44.0)	(44.1)	(41.0)	(48.7)	(41.4)		(39.6)	(43.0)	(37.5)	(45.6)	(37.3)	
Behavioral/												
lifestyle												
factors												
Smoking												
status						< 0.001						< 0.001
Never	35,339	21,080	7,930	1,788	2,300		3,885	6160	1020	251	399	
smoker	(31.8)	(55.1)	(45.9)	(44.1)	(37.0)		(43.4)	(69.6)	(58.9)	(61.4)	(48.8)	
	58,433	13,638	6,166	1,376	2,852		3,728	2061	464	101	305	
Current	(52.6)	(35.6)	(35.7)	(33.9)	(45.9)		(41.6)	(23.4)	(26.8)	(24.7)	(37.3)	
	17,276	3,554	3,169	890	1,068		1,341	594	247	57	114	
Past	(15.6)	(9.3)	(18.4)	(22.0)	(17.2)		(15.0)	(6.7)	(14.3)	(13.9)	(13.9)	
BMI						< 0.001						< 0.001
Normal/	16,278	4,244	1,607	708	684		3,192	2,017	591	203	259	
underweight	(14.6)	(11.1)	(9.3)	(17.4)	(11.0)		(35.5)	(22.8)	(34.0)	(49.3)	(31.5)	
	42,832	12,982	6,307	1,998	2,237		3,036	3,235	604	123	263	
Overweight	(38.4)	(33.8)	(36.4)	(49.0)	(35.8)		(33.8)	(36.6)	(34.8)	(29.9)	(32.0)	
	52,377	21195	9,408	1,370	3,326		2,764	3,600	541	86	300	
Obese	(47.0)	(55.2)	(54.3)	(33.6)	(53.2)		(30.7)	(40.7)	(31.2)	(20.9)	(36.5)	
Alcohol or												
drug use												
disorder						< 0.001						< 0.001
	64,998	22,875	10,048	2,767	3,631		5,734	5,896	1,138	277	502	
No	(67.5)	(72.1)	(67.3)	(83.5)	(68.2)		(76.8)	(82.1)	(77.5)	(85.5)	(73.8)	
	31,322	8,863	4,885	548	1695		1,728	1,285	330	47	178	
Yes	(32.5)	(27.9)	(32.7)	(16.5)	(31.8)		(23.2)	(17.9)	(22.5)	(14.5)	(26.2)	
Clinical												
factors												
MST history						0.0016						< 0.001
	93,007	30,880	14,474	3,214	5,160		4,735	5,,060	887	232	428	
No	(97.6)	(98.0)	(97.7)	(97.9)	(97.8)		(63.9)	(70.8)	(60.8)	(72.5)	(63.6)	
		645	342	69	118		2,679	2086	572	88	245	
Yes	2328 (2.4)	(2.1)	(2.3)	(2.1)	(2.2)		(36.1)	(29.2)	(39.2)	(27.5)	(36.4)	

PTSD						< 0.001					< 0.001
	35,578	11,735	4,433	1,699	1,766	2,907	2,797	460	160	251	
No	(36.9)	(37.0)	(29.7)	(51.3)	(33.2)	(39.0)	(39.0)	(31.3)	(49.4)	(36.9)	
	60,742	20,003	10,500	1,616	3,560	4,555	4,384	1,008	164	429	
Yes	(63.1)	(63.0)	(70.3)	(48.8)	(66.8)	(61.0)	(61.1)	(68.7)	(50.6)	(63.1)	
MDD						< 0.001					< 0.001
	54,776	18,386	7,787	2,044	2,997	3,041	2,775	509	151	260	
No	(56.9)	(57.9)	(52.2)	(61.7)	(56.3)	(40.8)	(38.6)	(34.7)	(46.6)	(38.2)	
	41,544	13,352	7,146	1,271	2,329	4,421	4,406	959	173	420	
Yes	(43.1)	(42.1)	(47.9)	(38.3)	(43.7)	(59.3)	(61.4)	(65.3)	(53.4)	(61.8)	
GAD						< 0.001					< 0.001
	84,593	29,586	13,306	3,035	4,800	5,868	6,160	1,178	278	572	
No	(87.8)	(93.2)	(89.1)	(91.6)	(90.1)	(78.6)	(85.8)	(80.3)	(85.8)	(84.1)	
	11,727	2,152	1,627	280	526	1,594	1,021	290	46	108	
Yes	(12.2)	(6.8)	(10.9)	(8.5)	(9.9)	(21.4)	(14.2)	(19.8)	(14.2)	(15.9)	
Diabetes						< 0.001					< 0.001
	79,036	22,199	10,891	2,259	3,867	6,640	5,604	1,221	232	550	
No	(82.1)	(69.9)	(72.9)	(68.1)	(72.6)	(89.0)	(78.0)	(83.2)	(71.6)	(80.9)	
	17,284	9,539	4,042	1,056	1,459	822	1,577	247	92	130	
Yes	(17.9)	(30.1)	(27.1)	(31.9)	(27.4)	(11.0)	(22.0)	(16.8)	(28.4)	(19.1)	
Dyslipidemia						< 0.001					0.0378
	52,937	18,650	7,758	1,809	2,897	5,844	5,718	1,118	237	541	
No	(47.5)	(48.5)	(44.8)	(44.4)	(46.4)	(65.0)	(64.6)	(64.4)	(57.5)	(65.8)	
	58,550	19,771	9,564	2,267	3,350	3,148	3,134	618	175	281	
Yes	(52.5)	(51.5)	(55.2)	(55.6)	(53.6)	(35.0)	(35.4)	(35.6)	(42.5)	(34.2)	
OSA						< 0.001					< 0.001
	60,451	16,545	7,786	1,757	3,088	5,850	5,021	1,086	234	511	
No	(62.8)	(52.1)	(52.1)	(53.0)	(58.0)	(78.4)	(69.9)	(74.0)	(72.2)	(75.2)	
	35,869	15,193	7,147	1,558	2,238	1,612	2,160	382	90	169	
Yes	(37.2)	(47.9)	(47.9)	(47.0)	(42.0)	(21.6)	(30.1)	(26.0)	(27.8)	(24.9)	
# of											
comorbidities						< 0.001					< 0.001
0		7,670	3,894	845	1541	1,865	1,481	344	56	167	
	30,229	,	,						$(1 - \alpha)$	$(\mathbf{a} + \mathbf{c})$	
<u>0</u> 1	30,229 (31.4) 34,511	(24.2) 10,753	(26.1) 5,308	(25.5)	(28.9) 1,838	(25.0) 3,067	(20.6) 2,894	(23.4) 597	(17.3) 129	(24.6) 248	

	(35.8)	(33.9)	(35.6)	(36.2)	(34.5)		(41.1)	(40.3)	(40.7)	(39.8)	(36.5)	
	15,688	5,637	2,832	637	900		1,456	1,486	307	79	144	
2	(16.3)	(17.8)	(19.0)	(19.2)	(16.9)		(19.5)	(20.7)	(20.9)	(24.4)	(21.2)	
	7,011	3,156	1,249	274	414		538	609	99	27	49	
3	(7.3)	(9.9)	(8.4)	(8.3)	(7.8)		(7.2)	(8.5)	(6.7)	(8.3)	(7.2)	
	4,079	2,027	748	173	294		267	334	63	17	36	
4	(4.2)	(6.4)	(5.0)	(5.2)	(5.5)		(3.6)	(4.7)	(4.3)	(5.3)	(5.3)	
	4,802	2,495	902	186	339		269	377	58	16	36	
5+	(5.0)	(7.9)	(6.0)	(5.6)	(6.4)		(3.6)	(5.3)	(4.0)	(4.9)	(5.3)	
Social												
deprivation												
SDI						< 0.001						< 0.001
Quartile 1												
(least												
disadvantage	33,354	6,165	3,025	956	1,430		2,617	1,381	304	99	190	
d)	(29.9)	(16.1)	(17.5)	(23.5)	(22.9)		(29.1)	(15.6)	(17.5)	(24.0)	(23.1)	
	29,682	7,669	3,447	1,087	1,601		2,433	1,853	406	125	199	
Quartile 2	(26.6)	(20.0)	(19.9)	(26.7)	(25.6)		(27.1)	(20.9)	(23.4)	(30.3)	(24.2)	
	28,505	10,099	3,872	805	1,483		2,186	2,398	408	80	210	
Quartile 3	(25.6)	(26.3)	(22.4)	(19.8)	(23.7)		(24.3)	(27.1)	(23.5)	(19.4)	(25.6)	
Quartile 4												
(most			< . - .							100		
disadvantage	19,946	14,488	6,978	1,228	1,733		1,756	3,220	618	108	223	
<u>d)</u>	(17.9)	(37.7)	(40.3)	(30.1)	(27.7)		(19.5)	(36.4)	(35.6)	(26.2)	(27.1)	
# of primary												
care visits, median										4		
(IQR)	3 (2-6)	3 (2-6)	4 (2-6)	3 (1-6)	3 (1-6)	< 0.001	4 (2-8)	4 (2-8)	4 (2-9)	4 (2-8)	4 (2-8)	0.378
Follow-up	3 (2-0)	3 (2-0)	4 (2-0)	5 (1-0)	5 (1-0)	<0.001	4 (2-0)	4 (2-0)	4 (2-9)	(2-8)	4 (2-0)	0.378
time period												
for analysis,		3.7							3.4			
median	3.4	(1.9-	3.5	3.5	3.4		3.4	3.8 (1.9-	(1.5-	3.3	3.6 (1.5-	
(IQR)	(1.5-4.4)	4.9)	(1.6-4.5)	(1.5-4.4)	(1.6-4.4)	< 0.001	(1.5-4.9)	4.6)	4.5)	(1.4-4.5)	4.5)	< 0.001
BP category†	(1.0 1.1)		(1.0 1.0)	(1.0 1.1)	(1.0 1.1)	<0.001	(1.0 1.7)	,		(111 110)	,	<0.001
<120/80	16,725	4,721	2,606	680	832	\0.001	3,069	2,160	677	115	284	<u>\0.001</u>
<120/00	10,723	4,/21	2,000	000	032		3,009	2,100	077	115	204	

mmHg	(15.0)	(12.3)	(15.0)	(16.7)	(13.3)		(34.1)	(24.4)	(39.0)	(27.9)	(34.6)	
120-												
129/<80	13,214	4,243	2,092	458	693		1,174	1,059	209	50	88	
mmHg	(11.9)	(11.0)	(12.1)	(11.2)	(11.1)		(13.1)	(12.0)	(12.0)	(12.1)	(10.7)	
130-139/80-	43,826	14,300	6,885	1,610	2,467		2,918	3,176	532	142	287	
89 mmHg	(39.3)	(37.2)	(39.8)	(39.5)	(39.5)		(32.5)	(35.9)	(30.7)	(34.5)	(34.9)	
140-159/90-	29,975	11,255	4,600	1,014	1,736		1,462	1,888	250	79	133	
99 mmHg	(26.9)	(29.3)	(26.6)	(24.9)	(27.8)		(16.3)	(21.3)	(14.4)	(19.2)	(16.2)	
≥160/100	7,746	3,902	1,139	314	519			569	68	26	30	
mmHg	(7.0)	(10.2)	(6.6)	(7.7)	(8.3)		369 (4.1)	(6.4)	(3.9)	(6.3)	(3.7)	
Count of												
antihyperten												
sive												
medication												
fills, median	7	8					4	6	4	5	5	
(IQR)	(2-15)	(3-17)	6 (2-15)	8 (3-17)	7 (3-16)	< 0.001	(2-11)	(2-13)	(2-10)	(2-13)	(2-11)	< 0.001
First AHM												
category						0.001						0.004
category prescribed					• • • •	< 0.001				100		< 0.001
prescribed	33,810	11,644	5899	1,402	2,067	< 0.001	3,393	1,907	693	100	275	<0.001
	(30.3)	(30.3)	(34.1)	(34.4)	(33.1)	<0.001	3,393 (37.7)	(21.5)	(39.9)	(24.3)	(33.5)	<0.001
prescribed ACEI	(30.3) 3,470	(30.3) 1,549	(34.1) 603	(34.4) 278	(33.1) 266	<0.001	(37.7)	(21.5) 292	(39.9) 39	(24.3) 25	(33.5) 24	<0.001
prescribed ACEI ARB	(30.3) 3,470 (3.1)	(30.3) 1,549 (4.0)	(34.1) 603 (3.5)	(34.4) 278 (6.8)	(33.1) 266 (4.3)	<0.001	(37.7) 209 (2.3)	(21.5) 292 (3.3)	(39.9) 39 (2.3)	(24.3) 25 (6.1)	(33.5) 24 (2.9)	<0.001
prescribed ACEI ARB Beta	(30.3) 3,470 (3.1) 22,674	(30.3) 1,549 (4.0) 3,598	(34.1) 603 (3.5) 3,266	(34.4) 278 (6.8) 556	(33.1) 266 (4.3) 1,059	<0.001	(37.7) 209 (2.3) 1,376	(21.5) 292 (3.3) 1,714	(39.9) 39 (2.3) 292	(24.3) 25 (6.1) 100	(33.5) 24 (2.9) 154	<0.001
prescribed ACEI ARB	(30.3) 3,470 (3.1) 22,674 (20.3)	(30.3) 1,549 (4.0) 3,598 (9.4)	(34.1) 603 (3.5) 3,266 (18.9)	(34.4) 278 (6.8) 556 (13.6)	(33.1) 266 (4.3) 1,059 (17.0)	<0.001	(37.7) 209 (2.3) 1,376 (15.3)	(21.5) 292 (3.3) 1,714 (19.4)	(39.9) 39 (2.3) 292 (16.8)	(24.3) 25 (6.1) 100 (24.3)	(33.5) 24 (2.9) 154 (18.7)	<0.001
prescribed ACEI ARB Beta blocker	(30.3) 3,470 (3.1) 22,674 (20.3) 14,671	(30.3) 1,549 (4.0) 3,598 (9.4) 10,316	(34.1) 603 (3.5) 3,266 (18.9) 2,525	(34.4) 278 (6.8) 556 (13.6) 606	(33.1) 266 (4.3) 1,059 (17.0) 965	<0.001	(37.7) 209 (2.3) 1,376 (15.3) 1,203	(21.5) 292 (3.3) 1,714 (19.4) 2,131	(39.9) 39 (2.3) 292 (16.8) 277	(24.3) 25 (6.1) 100 (24.3) 67	(33.5) 24 (2.9) 154 (18.7) 123	<0.001
prescribed ACEI ARB Beta blocker CCB	(30.3) 3,470 (3.1) 22,674 (20.3) 14,671 (13.2)	(30.3) 1,549 (4.0) 3,598 (9.4) 10,316 (26.9)	(34.1) 603 (3.5) 3,266 (18.9) 2,525 (14.6)	(34.4) 278 (6.8) 556 (13.6) 606 (14.9)	(33.1) 266 (4.3) 1,059 (17.0) 965 (15.5)	<0.001	(37.7) 209 (2.3) 1,376 (15.3) 1,203 (13.4)	(21.5) 292 (3.3) 1,714 (19.4) 2,131 (24.1)	(39.9) 39 (2.3) 292 (16.8) 277 (16.0)	(24.3) 25 (6.1) 100 (24.3) 67 (16.3)	(33.5) 24 (2.9) 154 (18.7) 123 (15.0)	<0.001
prescribed ACEI ARB Beta blocker CCB Thiazide	(30.3) 3,470 (3.1) 22,674 (20.3) 14,671 (13.2) 16,791	(30.3) 1,549 (4.0) 3,598 (9.4) 10,316 (26.9) 4,030	(34.1) 603 (3.5) 3,266 (18.9) 2,525 (14.6) 2,115	(34.4) 278 (6.8) 556 (13.6) 606 (14.9) 519	(33.1) 266 (4.3) 1,059 (17.0) 965 (15.5) 797	<0.001	(37.7) 209 (2.3) 1,376 (15.3) 1,203 (13.4) 1,797	(21.5) 292 (3.3) 1,714 (19.4) 2,131 (24.1) 1,281	(39.9) 39 (2.3) 292 (16.8) 277 (16.0) 252	(24.3) 25 (6.1) 100 (24.3) 67 (16.3) 61	(33.5) 24 (2.9) 154 (18.7) 123 (15.0) 160	<0.001
prescribed ACEI ARB Beta blocker CCB Thiazide diuretic	(30.3) 3,470 (3.1) 22,674 (20.3) 14,671 (13.2)	(30.3) 1,549 (4.0) 3,598 (9.4) 10,316 (26.9)	(34.1) 603 (3.5) 3,266 (18.9) 2,525 (14.6)	(34.4) 278 (6.8) 556 (13.6) 606 (14.9)	(33.1) 266 (4.3) 1,059 (17.0) 965 (15.5)	<0.001	(37.7) 209 (2.3) 1,376 (15.3) 1,203 (13.4)	(21.5) 292 (3.3) 1,714 (19.4) 2,131 (24.1)	(39.9) 39 (2.3) 292 (16.8) 277 (16.0)	(24.3) 25 (6.1) 100 (24.3) 67 (16.3)	(33.5) 24 (2.9) 154 (18.7) 123 (15.0)	<0.001
prescribed <u>ACEI</u> <u>ARB</u> Beta blocker <u>CCB</u> Thiazide diuretic Missing	(30.3) 3,470 (3.1) 22,674 (20.3) 14,671 (13.2) 16,791	(30.3) 1,549 (4.0) 3,598 (9.4) 10,316 (26.9) 4,030	(34.1) 603 (3.5) 3,266 (18.9) 2,525 (14.6) 2,115	(34.4) 278 (6.8) 556 (13.6) 606 (14.9) 519	(33.1) 266 (4.3) 1,059 (17.0) 965 (15.5) 797	<0.001	(37.7) 209 (2.3) 1,376 (15.3) 1,203 (13.4) 1,797	(21.5) 292 (3.3) 1,714 (19.4) 2,131 (24.1) 1,281	(39.9) 39 (2.3) 292 (16.8) 277 (16.0) 252	(24.3) 25 (6.1) 100 (24.3) 67 (16.3) 61	(33.5) 24 (2.9) 154 (18.7) 123 (15.0) 160	<0.001
prescribed <u>ACEI</u> <u>ARB</u> Beta blocker <u>CCB</u> Thiazide diuretic Missing (hypertensio	(30.3) 3,470 (3.1) 22,674 (20.3) 14,671 (13.2) 16,791 (15.1)	$\begin{array}{r} (30.3) \\ 1,549 \\ (4.0) \\ 3,598 \\ (9.4) \\ 10,316 \\ (26.9) \\ 4,030 \\ (10.5) \end{array}$	(34.1) 603 (3.5) 3,266 (18.9) 2,525 (14.6) 2,115 (12.2)	(34.4) 278 (6.8) 556 (13.6) 606 (14.9) 519 (12.7)	(33.1) 266 (4.3) 1,059 (17.0) 965 (15.5) 797 (12.8)	<0.001	(37.7) 209 (2.3) 1,376 (15.3) 1,203 (13.4) 1,797 (20.0)	(21.5) 292 (3.3) 1,714 (19.4) 2,131 (24.1) 1,281 (14.5)	(39.9) 39 (2.3) 292 (16.8) 277 (16.0) 252 (14.5)	(24.3) 25 (6.1) 100 (24.3) 67 (16.3) 61 (14.8)	(33.5) 24 (2.9) 154 (18.7) 123 (15.0) 160 (19.5)	<0.001
prescribed <u>ACEI</u> <u>ARB</u> Beta blocker <u>CCB</u> Thiazide diuretic Missing	(30.3) 3,470 (3.1) 22,674 (20.3) 14,671 (13.2) 16,791	(30.3) 1,549 (4.0) 3,598 (9.4) 10,316 (26.9) 4,030	(34.1) 603 (3.5) 3,266 (18.9) 2,525 (14.6) 2,115	(34.4) 278 (6.8) 556 (13.6) 606 (14.9) 519	(33.1) 266 (4.3) 1,059 (17.0) 965 (15.5) 797	<0.001	(37.7) 209 (2.3) 1,376 (15.3) 1,203 (13.4) 1,797	(21.5) 292 (3.3) 1,714 (19.4) 2,131 (24.1) 1,281	(39.9) 39 (2.3) 292 (16.8) 277 (16.0) 252	(24.3) 25 (6.1) 100 (24.3) 67 (16.3) 61	(33.5) 24 (2.9) 154 (18.7) 123 (15.0) 160	<0.001

Abbreviations: ACEI, angiotensin converting enzyme inhibitor; AHM, antihypertensive medication; ARB, angiotensin II receptor blocker; BMI, body mass index; CCB, calcium channel blocker; EHR, electronic health record; GAD, generalized anxiety disorder; IQR, interquartile range; MDD,

major depressive disorder; MST, military sexual trauma; NH, non-Hispanic; OSA, obstructive sleep apnea; PTSD, posttraumatic stress disorder; SDI, Social Deprivation Index

Notes. Data are presented as N (%). All other data are presented as median (Q1, Q3).P-value tests differences across all sex, race, and ethnicity groups using chi-square test for categorical variables, Kruskal-Wallis test for continuous non-normally distributed variables. If an individual was in 2 different categories based on systolic and diastolic BP, they were placed in the higher BP category. SDI Quartile 1=least disadvantaged and Quartile 4=most disadvantaged

									`			
	Men (<i>n</i> =	177,553)					Women	(<i>n</i> =20,814	/			
	Year 1		Year 2		Year 5		Year 1		Year 2		Year 5	
	n (%)	Р	n (%)	Р	n (%)	Р	n (%)	Р	n (%)	Р	n (%)	Р
	87,172		93,067		94,266		13,363		13,670		13,673	
Total	(55.4)		(54.2)		(53.1)		(69.1)		(67.0)		(65.7)	
Demographics												
Age (years)												
* *	56,673		59,807		60,436		10,193		10,357		10,378	
<40	(56.5)	< 0.001	(55.1)	< 0.001	(54.0)	< 0.001	(73.2)	< 0.001	(71.0)	< 0.001	(70.0)	< 0.001
	30,499		33,260		33,830		3,170		3,313		3,295	
≥40	(53.7)		(52.6)		(51.6)		(58.6)		(57.0)		(55.1)	
Race and ethnicity		< 0.001		< 0.001		< 0.001		< 0.001		< 0.001		< 0.001
-	55,783		59,762		60,557		6,146		6,340		6,370	
NH White	(56.6)		(55.4)		(54.3)		(73.4)		(71.8)		(70.8)	
	17,324		18,317		18,452		5,193		5,262		5,242	
NH Black	(50.9)		(49.4)		(48.0)		(63.5)		(60.9)		(59.2)	
	8,983		9,503		9,604		1,231		1,242		1,256	
Hispanic	(57.7)		(56.6)		(55.4)		(75.2)		(72.8)		(72.4)	
	2,099		2,277		2,305		254		264		265	
NH Asian	(58.9)		(57.8)		(56.6)		(67.6)		(65.2)		(64.3)	
	2,983		3,208		3,348		539		562		540	
NH Other	(54.2)		(53.2)		(53.6)		(70.1)		(69.3)		(65.7)	
Marital status		< 0.001		< 0.001		< 0.001		0.012		0.011		0.056
	36,262		38,354		38,937		8,130		8,290		8,272	
Not married	(54.9)		(53.4)		(52.5)		(69.8)		(67.7)		(66.2)	
	50,884		54,677		55,291		5,217		5,364		5,385	
Married	(55.9)		(54.7)		(53.6)		(68.1)		(66.0)		(64.0)	
Education		< 0.001		< 0.001		< 0.001		< 0.001		0.006		< 0.001
	19,436		21,226		21,438		3,639		3,836		3,808	
>High school	(57.7)		(56.7)		(55.3)		(66.4)		(65.6)		(63.7)	
	67,720		71,827		72,815		9,722		9,833		9,864	
≥High school	(54.8)		(53.5)		(52.5)		(70.2)		(67.6)		(66.5)	

Table 4. Proportion of the cohort with controlled BP at years 1, 2, 5 after a hypertension diagnosis, by descriptive and clinical factors, n=198,367

Rurality of residence		0.405		0.849		0.105		0.007		0.110		0.019
	60,428		64,530		65,234		10,362		10,624		10,603	
Urban	(55.4)		(54.2)		(53.0)		(68.7)		(66.7)		(65.3)	
	26,742		28,536		29,031		3,001		3,046		3,070	
Rural	(55.6)		(54.2)		(53.4)		(70.8)		(68.0)		(67.2)	
Additional health												
insurance		< 0.001		< 0.001		< 0.001		0.635		0.042		0.088
	40,044		42,296		42,812		6,340		6,510		6,512	
No	(54.1)		(52.8)		(51.7)		(69.1)		(67.7)		(66.6)	
	32,402		34,909		35,435		4,283		4,375		4,411	
Yes	(57.2)		(56.1)		(55.0)		(68.8)		(66.1)		(65.3)	
Behavioral/lifestyle												
factors												
Smoking status		< 0.001		< 0.001		< 0.001		0.064		0.056		0.003
	34,166		36,623		37,197		7,502		7,713		7,635	
Never smoker	(56.8)		(55.4)		(54.4)		(69.2)		(67.2)		(65.2)	
	12,945		14,070		14,240		1,538		1,586		1,619	
Past smoker	(56.7)		(56.0)		(54.9)		(71.1)		(68.9)		(68.8)	
	39,756		42,044		42,489		4,268		4,319		4,367	
Current smoker	(54.0)		(52.6)		(51.5)		(68.4)		(66.2)		(65.6)	
BMI		< 0.001		< 0.001		< 0.001		< 0.001		< 0.001		< 0.00
	13,397		14,128		14,258		4,414		4,525		4,521	
Normal/underweight	(63.6)		(62.0)		(60.6)		(75.7)		(73.7)		(72.2)	
0	33,793		36,031		36,459		4,632		4,771		4,775	
Overweight	(57.5)		(56.1)		(54.9)		(68.7)		(67.0)		(65.8)	
	39,982		42,908		43,549		4,317		4,374		4,377	
Obese	(51.7)		(50.7)		(49.7)		(63.9)		(61.3)		(60.0)	
Alcohol or drug use							. ,		. ,			
disorder		< 0.001		< 0.001		< 0.001		0.147		0.006		0.119
	52,097		55,932		56,750		8,683		8,961		8,974	
No	(56.9)		(55.5)		(54.4)		(69.3)		(67.5)		(66.2)	
	22,565		23,654		23,860		2,302		2,286		2,314	
Yes	(52.5)		(51.5)		(50.4)		(68.0)		(65.0)		(64.9)	
Clinical factors												
MST history		0.157		0.983		0.808		0.182		0.013		0.191

	72,209		77,024		78,008		7,195		7,374	,	7,443	
No	(55.5)		(54.3)		(53.2)		(68.7)		(66.3)		(65.6)	
	1,789		1,843		1,869		3,725		3,804		3,778	
Yes	(56.7)		(54.2)		(53.4)		(69.7)		(68.3)		(66.6)	
PTSD		0.263		0.184		0.369		< 0.001		< 0.001		< 0.001
	26,129		28,658		29,267		4,028		4,202		4,157	
No	(55.3)		(54.0)		(53.0)		(67.3)		(65.4)		(63.2)	
	48,533		50,928		51,343		6,957		7,045	,	7,131	
Yes	(55.6)		(54.4)		(53.3)		(70.0)		(68.0)		(67.7)	
MDD		0.040		0.171		0.515		0.004		0.635		0.002
	41,589		45,063		45,651		4,145		4,396		4,350	
No	(55.8)		(54.4)		(53.1)		(67.7)		(66.8)		(64.6)	
	33,073		34,523		34,959		6,840		6,851		6,938	
Yes	(55.2)		(54.1)		(53.3)		(69.8)		(67.1)		(66.9)	
GAD		< 0.001		< 0.001		0.004		< 0.001		< 0.001		< 0.001
	66,168		70,730		71,765		8,893		9,132		9,162	
No	(55.3)		(54.1)		(53.0)		(68.3)		(66.3)		(65.2)	
	8,494		8,856		8,845		2,092		2,115		2,126	
Yes	(57.2)		(55.8)		(54.2)		(72.1)		(70.1)		(69.5)	
Diabetes		< 0.001		< 0.001		0.014		< 0.001		< 0.001		< 0.001
	58,309		62,307		63,062		9,265		9,512		9,565	
No	(55.9)		(54.6)		(53.3)		(69.9)		(68.0)		(67.1)	
	16,353		17,279		17,548		1,720		1,735		1,723	
Yes	(54.2)		(53.2)		(52.6)		(64.3)		(61.7)		(60.1)	
Dyslipidemia		0.435		0.871		0.331		< 0.001		< 0.001		< 0.001
<u>_</u>	40,902		43,852		44,522		8,790		9,054		9,073	
No	(55.6)		(54.2)		(53.0)		(70.6)		(68.8)		(67.4)	
	46,270		49,215		49,744		4,573		4,616		4,600	
Yes	(55.4)		(54.2)		(53.2)		(66.4)		(63.8)		(62.5)	
OSA		< 0.001		< 0.001		< 0.001		< 0.001		< 0.001		< 0.001
	44,169		47,755		48,241		8,312		8,485		8,582	
No	(56.4)		(55.3)		(53.8)		(70.7)		(68.2)		(67.6)	
	30,493		31,831		32,369		2,673		2,762		2,706	
Yes	(54.3)		(52.8)		(52.2)		(64.2)		(63.6)		(61.3)	
Number of		< 0.001		0.008		< 0.001		< 0.001		< 0.001		< 0.001
					24	~						

comorbidities												
	20,791		22,838		23,218		2,442		2,581		2,625	
0	(55.9)		(54.3)		(52.6)		(69.6)		(67.9)		(67.1)	
	26,898		28,492		28,844		4,561		4,709		4,686	
1	(56.3)		(54.8)		(53.8)		(70.6)		(69.1)		(67.6)	
	12,835		13,507		13,557		2,279		2,259		2,268	
2	(54.7)		(53.9)		(52.8)		(69.3)		(66.1)		(65.3)	
	6,119		6,374		6,521		810		817		833	
3	(54.9)		(53.8)		(53.9)		(64.8)		(62.7)		(63.0)	
	3,687		3,860		3,901		457		439		437	
4	(54.5)		(54.1)		(53.3)		(66.3)		(62.2)		(61.0)	
	4,332		4,515		4,569		436		442		439	
5+	(52.9)		(52.8)		(52.4)		(60.0)		(59.3)		(58.1)	
SDI												
Quartile 1	22,321		24,054		24,227		2,978		3,097		8,092	
	(56.5)	< 0.001	(55.4)	< 0.001	(53.9)	< 0.001	(70.2)	0.008	(68.8)	0.012	(67.4)	< 0.001
Quartile 2	21,446		22,946		23,275		3,258		3,300		3,363	
	(55.7)		(54.5)		(53.5)		(70.0)		(67.1)		(67.1)	
Quartile 3	21,965		23,441		23,898		3,393		3,466		3,442	
	(55.4)		(54.1)		(53.4)		(69.3)		(66.9)		(65.2)	
Quartile 4	21,440		22,626		22,866		3,734		3,807		3,776	
	(54.2)		(52.7)		(51.5)		(67.4)		(65.7)		(63.7)	

comorbidities

Abbreviations: ACEI, angiotensin converting enzyme inhibitor; AHM, antihypertensive medication; ARB, angiotensin II receptor blocker; BMI, body mass index; EHR, electronic health record; GAD, generalized anxiety disorder; IQR, interquartile range; MDD, major depressive disorder; MST, military sexual trauma; NH, non-Hispanic; OSA, obstructive sleep apnea; PTSD, posttraumatic stress disorder; SDI, Social Deprivation Index

Note. Data presented are N (%) unless otherwise indicated. SDI Quartile 1=least disadvantaged and Quartile 4=most disadvantaged


Year 5 Year 1 Year 2 OR OR OR Р Р Р (95% CI) (95% CI) (95% CI) 1.66 1.62 1.60 < 0.001 < 0.001 < 0.001 Women (1.59-1.73)(1.54 - 1.71)(1.53 - 1.69)**Demographics** <40 years 1.24 1.22 1.20 < 0.001 < 0.001 < 0.001 (1.20-1.28)(1.19-1.26)(1.16-1.23) $(vs \ge 40 years)$ 0.78 0.76 0.78 Black (vs White) < 0.001 < 0.001 < 0.001 (0.74 - 0.79)(0.75 - 0.81)(0.75 - 0.80)1.09 1.04 1.08 Hispanic (vs White) < 0.001 < 0.001 0.093 (0.99-1.09)(1.04 - 1.14)(1.03 - 1.13)0.90 0.99 0.98 Asian (vs White) 0.038 0.770 0.621 (0.81 - 0.99)(0.90 - 1.09)(0.89 - 1.07)0.87 0.89 0.93 Other (vs White) < 0.001 0.002 0.039 (0.80-0.93)(0.83 - 0.96)(0.87 - 1.00)0.92 0.92 0.93 Not married (vs married) < 0.001 < 0.001 < 0.001 (0.90-0.95)(0.89 - 0.94)(0.91 - 0.96)**Behavioral/lifestyle factors** 0.96 0.98 1.00 0.925 Past smoker (vs never) 0.073 0.409 (0.92 - 1.00)(0.94 - 1.02)(0.96 - 1.04)0.88 0.88 0.88 < 0.001 < 0.001 < 0.001 Current smoker (vs never) (0.85 - 0.91)(0.85 - 0.91)(0.85 - 0.90)0.73 0.75 0.76 Overweight (vs normal/under) < 0.001 < 0.001 < 0.001 (0.70 - 0.76)(0.73 - 0.79)(0.73 - 0.79)0.56 0.59 0.57 Obese (vs normal/under) < 0.001 < 0.001 < 0.001 (0.54 - 0.58)(0.55 - 0.60)(0.56 - 0.61)0.80 0.81 0.79 Alcohol abuse or drug use (vs never) < 0.001 < 0.001 < 0.001 (0.77 - 0.82)(0.78 - 0.83)(0.78 - 0.83)**Clinical risk factors** 0.99 1.05 1.04 0.135 0.297 0.685 MST ever (vs no history) (0.98 - 1.13)(0.97 - 1.10)(0.93 - 1.05)PTSD ever (vs never) 1.07 < 0.001 1.07 < 0.001 1.06 < 0.001

Table 5. Multivariable Models for the Effects of Sex on Odds of BP Control at 1, 2, and 5 Years.

	(1.04-1.11)		(1.04-1.10)		(1.03-1.09)	
# of comorbidities	1.00 (0.99-1.01)	0.412	1.01 (1.00-1.01)	0.237	1.01 (1.00-1.02)	0.005
OSA ever (vs never)	1.00 (1.00-1.00)	0.197	1.00 (1.00-1.01)	0.054	1.01 (1.00-1.01)	0.058
Diabetes (vs none)	0.98 (0.95-1.01)	0.153	0.94 (0.92-0.97)	0.282	0.97 (0.95-1.00)	0.581
Dyslipidemia (vs none)	1.03 (0.99-1.07)	0.160	1.02 (0.98-1.06)	0.563	1.01 (0.97-1.05)	0.282
Primary care utilization						
# of visits in the first 2 years	1.02 (0.99-1.05)	0.312	1.01 (0.98-1.04)	0.023	1.02 (0.99-1.05)	< 0.001

Abbreviations: CI, confidence interval; MST, military sexual trauma; OR, odds ratio; OSA, obstructive sleep apnea; PTSD, posttraumatic stress disorder; SDI, Social Deprivation Index

Figure 1. Study flowchart of the cohort of post-9/11 men and women Veterans.



References

- 1. Hinojosa R. Veterans' likelihood of reporting cardiovascular disease. J Am Board Fam Med. 2019; 32:50-57. doi:10.3122/jabfm.2019.01.180148.
- 2. Assari S. Veterans and risk of heart disease in the United States: a cohort with 20 years of follow up. Int J Prev Med. 2014; 5:703. doi:10.1177/107424842210910.
- 3. Weitlauf JC, LaCroix AZ, Bird CE, Woods NF, Washington DL, Katon JG, LaMonte MJ, Goldstein MK, Bassuk SS, Sarto GE. Prospective analysis of health and mortality risk in veteran and non-veteran participants in the Women's Health Initiative. Women's Health Issues. 2015; 25:649-657. doi:10.1016/j.whi.2015.08.006.
- 4. Fryar CD, Herrick K, Afful J, Ogden CL. Cardiovascular disease risk factors among male veterans, US, 2009–2012. Am J Prev Med. 2016; 50:101-105. doi:10.1016/j.amepre.2015.06.011.
- 5. Haskell SG, Brandt C, Burg M, Bastian L, Driscoll M, Goulet J, Mattocks K, Dziura J. Incident cardiovascular risk factors among men and women veterans after return from deployment. Med Care. 2017; 55:948-955. doi:10.1097/MLR.0000000000000801.
- Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Himmelfarb CD, DePalma SM, Gidding S, Jamerson KA, Jones DW. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention,

detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018; 71:e127-e248. doi:10.1016/j.jacc.2017.11.006.

- Gaffey AE, Haskell SG, Brandt CA, Bastian LA, Meadows JL, Burg MM. Post-9/11 veterans' heart disease knowledge, self-perceived risk, and prevention beliefs and behaviors. Health Psychol. 2021; 40:737-746. doi:10.1037/hea0001110.
- 8. Rana J, Oldroyd J, Islam MM, Tarazona-Meza CE, Islam RM. Prevalence of hypertension and controlled hypertension among United States adults: evidence from NHANES 2017-18 survey. Int J Cardiol Hypertens. 2020; 7:100061. doi:10.1016/j.ijchy.2020.100061.
- 9. Egan BM, Li J, Sutherland SE, Rakotz MK, Wozniak GD. Hypertension control in the United States 2009 to 2018: factors underlying falling control rates during 2015 to 2018 across age-and race-ethnicity groups. Hypertension. 2021; 78:578-587. doi:10.1161/HYPERTENSIONAHA.120.16418.
- 10. Affairs DoV. Women veterans report: The past, present, and future of women veterans. Washington, DC: National Center for Veterans Analysis and Statistics. 2017:1-72. doi.
- 11. Zhang Y, Moran AE. Trends in the prevalence, awareness, treatment, and control of hypertension among young adults in the United States, 1999 to 2014. Hypertension. 2017; 70:736-742. doi:10.1161/HYPERTENSIONAHA.117.09801.
- 12. Haskell SG, Mattocks K, Goulet JL, Krebs EE, Skanderson M, Leslie D, Justice AC, Yano EM, Brandt C. The burden of illness in the first year home: Do male and female VA users differ in health conditions and healthcare utilization. Womens Health Issues. 2011; 21:92-97. doi:10.1016/j.whi.2010.08.001.
- 13. Gaffey AE, Burg MM, Rosman L, Portnoy GA, Brandt CA, Cavanagh CE, Skanderson M, Dziura J, Mattocks KM, Bastian LA. Baseline characteristics from the Women Veterans Cohort Study: gender differences and similarities in health and healthcare utilization. J Womens Health. 2021; 30:944-955. doi:10.1089/jwh.2020.8732.
- 14. National Center for Veterans Analysis and Statistics. Race Distribution. Profile of Post-9/11 Veterans: 2016. 2016:1-33. doi.
- 15. Seth S. Martin M, MHS, FAHA, Chair; Aaron W. Aday, MD, MSc, FAHA; Zaid I. Almarzooq, MBBCh, MPH; Cheryl A.M. Anderson, PhD, MPH, FAHA; Pankaj Arora, MD, FAHA; Christy L. Avery, PhD, MPH, FAHA; Carissa M. Baker-Smith, MD, MPH, FAHA; Bethany Barone Gibbs, PhD, MSc, FAHA; Andrea Z. Beaton, MD, MS, FAHA; Amelia K. Boehme, PhD, MSPH; Yvonne Commodore-Mensah, PhD, MHS, RN, FAHA; Maria E. Currie, MD, PhD; Mitchell S.V. Elkind, MD, MS, FAHA; Kelly R. Evenson, PhD, MS, FAHA; Giuliano Generoso, MD, PhD; Debra G. Heard, PhD;

Swapnil Hiremath, MD, MPH, FAHA; Michelle C. Johansen, MD, PhD; Rizwan Kalani, MD; Dhruv S. Kazi, MD, MSc, MS, FAHA; Darae Ko, MD, MSc; Junxiu Liu, PhD; Jared W. Magnani, MD, MS, FAHA; Erin D. Michos, MD, MHSc, FAHA; Michael E. Mussolino, PhD, FAHA; Sankar D. Navaneethan, MD, MS, MPH; Nisha I. Parikh, MD, MPH; Sarah M. Perman, MD, MSCE, MS, FAHA; Remy Poudel, MS, MPH, CPH; Mary Rezk-Hanna, PhD, FAHA; Gregory A. Roth, MD, MPH, FAHA; Nilay S. Shah, MD, MPH, FAHA; Marie-Pierre St-Onge, PhD, FAHA; Evan L. Thacker, PhD; Connie W. Tsao, MD, MPH, FAHA; Sarah M. Urbut, MD, PhD; Harriette G.C. Van Spall, MD, MPH; Jenifer H. Voeks, PhD, FAHA; Nae-Yuh Wang, PhD, MS, FAHA; Nathan D. Wong, PhD, MPH, FAHA; Sally S. Wong, PhD, RD, CDN, FAHA; Kristine Yaffe, MD; Latha P. Palaniappan, MD, MS, FAHA, Vice Chair; on behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. Circulation. 2024; 149:e00–e00. doi:10.1161/CIR.00000000001209.

- 16. Osude N, Durazo-Arvizu R, Markossian T, Liu K, Michos ED, Rakotz M, Wozniak G, Egan B, Kramer H. Age and sex disparities in hypertension control: the multi-ethnic study of atherosclerosis (MESA). Am J Prev Cardiol. 2021; 8:100230. doi:10.1016/j.ajpc.2021.100230.
- 17. Chaturvedi A, Zhu A, Vaishnavi Gadela N, Prabhakaran D, Jafar TH. Social determinants of health and disparities in hypertension and cardiovascular diseases. Hypertension. 2024; 81:387-399. doi:10.1161/HYPERTENSIONAHA.123.21354.
- Brandt EJ, Tobb K, Cambron JC, Ferdinand K, Douglass P, Nguyen PK, Vijayaraghavan K, Islam S, Thamman R, Rahman S. Assessing and Addressing Social Determinants of Cardiovascular Health: JACC State-of-the-Art Review. J Am Coll Cardiol. 2023; 81:1368-1385. doi:10.1016/j.jacc.2023.01.042.
- 19. Doyle SK, Chang AM, Levy P, Rising KL. Achieving health equity in hypertension management through addressing the social determinants of health. Curr Hypertens Rep. 2019; 21:1-6. doi:10.1007/s11906-019-0962-7.
- 20. Razon Ma, Hessler D, Bibbins-Domingo K, Gottlieb L. How hypertension guidelines address social determinants of health: a systematic scoping review. Med Care. 2021; 59:1122-1129. doi:10.1097/MLR.00000000001649.
- 21. Blosnich JR, Dichter ME, Gurewich D, Montgomery AE, Kressin NR, Lee R, Hester CM, Hausmann LR. Health services research and social determinants of health in the nation's largest integrated health care system: steps and leaps in the Veterans Health Administration. Mil Med. 2020; 185:e1353-e1356. doi:10.1093/milmed/usaa067.
- 22. Butler DC, Petterson S, Phillips RL, Bazemore AW. Measures of social deprivation that predict health care access and need within a rational area of primary care service delivery. Health Serv Res. 2013; 48:539-559. doi:10.1111/j.1475-6773.2012.01449.x.
- 23. Lu Y, Linderman GC, Mahajan S, Liu Y, Huang C, Khera R, Mortazavi BJ, Spatz ES, Krumholz HM. Quantifying blood pressure visit-to-visit variability in the real-world setting: A retrospective cohort study. Circ Cardiovasc Qual Outcomes. 2023; 16:e009258. doi:10.1161/CIRCOUTCOMES.122.009258.
- 24. Burg MM, Brandt C, Buta E, Schwartz J, Bathulapalli H, Dziura J, Edmondson DE, Haskell S. Risk for incident hypertension associated with PTSD in military veterans, and the effect of PTSD treatment. Psychosom Med. 2017; 79:181. doi:10.1097/PSY.00000000000376.
- 25. Muntner P, Miles MA, Jaeger BC, Hannon Iii L, Hardy ST, Ostchega Y, Wozniak G, Schwartz JE. Blood pressure control among US adults, 2009 to 2012 through 2017 to 2020. Hypertension. 2022; 79:1971-1980. doi:10.1161/HYPERTENSIONAHA.122.19222.
- 26. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American

College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2018; 71:e127-e248. doi.

- 27. Gaffey AE, Rosman L, Sico JJ, Haskell SG, Brandt CA, Bathulapalli H, Han L, Dziura J, Skanderson M, Burg MM. Military sexual trauma and incident hypertension: A 16-year cohort study of young and middle-aged men and women. J Hypertens. 2022; 40:2307-2315. doi:10.1097/HJH.00000000003267.
- 28. D'Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the Charlson comorbidity index with administrative data bases. J Clin Epidemiol. 1996; 49:1429-1433. doi:10.1016/s0895-4356(96)00271-5.
- 29. Gaffey AE, Rosman L, Burg MM, Haskell SG, Brandt CA, Skanderson M, Dziura J, Sico JJ. Posttraumatic stress disorder, antidepressant use, and hemorrhagic stroke in young men and women: a 13-year cohort study. Stroke. 2021; 52:121-129. doi:10.1161/STROKEAHA.120.030379.
- 30. Whelton PK, Carey RM. The 2017 clinical practice guideline for high blood pressure. JAMA. 2017; 318:2073-2074. doi:10.1001/jama.2017.18209.
- 31. Ostchega Y, Fryar CD, Nwankwo T, Nguyen DT. Hypertension prevalence among adults aged 18 and over: United States, 2017–2018. NCHS Data Brief. 2020; 364:1-8. doi.
- 32. Kang HK, Bullman TA. Mortality among US veterans of the Persian Gulf War. N Engl J Med. 1996; 335:1498-1504. doi:10.1056/NEJM199611143352006.
- 33. McLaughlin R, Nielsen L, Waller M. An evaluation of the effect of military service on mortality: quantifying the healthy soldier effect. Ann Epidemiol. 2008; 18:928-936. doi:10.1016/j.annepidem.2008.09.002.
- 34. Ji H, Niiranen TJ, Rader F, Henglin M, Kim A, Ebinger JE, Claggett B, Merz CNB, Cheng S. Sex differences in blood pressure associations with cardiovascular outcomes. Circulation. 2021; 143:761-763. doi:10.1161/CIRCULATIONAHA.120.049360.
- 35. Dhruva SS, Dziura J, Bathulapalli H, Rosman L, Gaffey AE, Davis MB, Brandt CA, Haskell SG. Gender differences in guideline-directed medical therapy for cardiovascular disease among young veterans. J Gen Intern Med. 2022; 37:806-815. doi.
- 36. Hales CM, Carroll MD, Simon PA, Kuo T, Ogden CL. Hypertension prevalence, awareness, treatment, and control among adults aged≥ 18 years—Los Angeles county, 1999–2006 and 2007–2014. MMWR Morb Mortal Wkly Rep. 2017; 66:846. doi:10.15585/mmwr.mm6632a3.
- 37. Redfern A, Peters SA, Luo R, Cheng Y, Li C, Wang J, Anderson C, Wang H, Norton R. Sex differences in the awareness, treatment, and control of hypertension in China: a systematic review with metaanalyses. Hypertens Res. 2019; 42:273-283. doi:10.1038/s41440-018-0154-x.
- 38. Everett B, Zajacova A. Gender differences in hypertension and hypertension awareness among young adults. Biodemography Soc Biol. 2015; 61:1-17. doi:10.1080/19485565.2014.929488.
- 39. Connelly PJ, Currie G, Delles C. Sex differences in the prevalence, outcomes and management of hypertension. Ciurr Hypertens Rep. 2022; 24:185-192. doi:10.1007/s11906-022-01183-8.
- 40. Tschanz CMP, Cushman WC, Harrell CTE, Berlowitz DR, Sall JL. Synopsis of the 2020 US Department of Veterans Affairs/US Department of Defense clinical practice guideline: the diagnosis and management of hypertension in the primary care setting. Ann Intern Med. 2020; 173:904-913. doi:10.7326/M20-3798.
- 41. Fletcher RD, Amdur RL, Kolodner R, McManus C, Jones R, Faselis C, Kokkinos P, Singh S, Papademetriou V. Blood pressure control among US veterans: a large multiyear analysis of blood pressure data from the Veterans Administration health data repository. Circulation. 2012; 125:2462-2468. doi:10.1161/CIRCULATIONAHA.111.029983.
- 42. Raghavan S, Ho Y-L, Kini V, Rhee MK, Vassy JL, Gagnon DR, Cho K, Wilson PW, Phillips LS. Association between early hypertension control and cardiovascular disease incidence in Veterans with diabetes. Diabetes Care. 2019; 42:1995-2003. doi:10.2337/dc19-0686.
- 43. Whitehead AM, Maher NH, Goldstein K, Bean-Mayberry B, Duvernoy C, Davis M, Safdar B, Saechao F, Lee J, Frayne SM. Sex differences in Veterans' cardiovascular health. J Womens Health. 2019; 28:1418-1427. doi:10.1089/jwh.2018.7228.

- 44. Saha S, Freeman M, Toure J, Tippens KM, Weeks C, Ibrahim S. Racial and ethnic disparities in the VA health care system: a systematic review. J Gen intern Med. 2008; 23:654-671. doi:10.1007/s11606-008-0521-4.
- 45. Carter A, Borrero S, Wessel C, Washington DL, Bean-Mayberry B, Corbelli J, Batch BC, Breland JY, DiLeone B, Foynes MM. Racial and ethnic health care disparities among women in the veterans affairs healthcare system: a systematic review. Womens Health Issues. 2016; 26:401-409. doi:10.1016/j.whi.2016.03.009.
- 46. Meyerovitz CV, Juraschek SP, Ayturk D, Moore Simas TA, Person SD, Lemon SC, McManus DD, Kovell LC. Social determinants, blood pressure control, and racial inequities in childbearing age women with hypertension, 2001 to 2018. J Am Heart Assoc. 2023; 12:e027169. doi:10.1161/JAHA.122.027169.
- 47. Aboumrad M, Peritz D, Friedman S, Zwain G, Watts BV, Taub C. Rural-urban trends in health care utilization, treatment, and mortality among US veterans with congestive heart failure: A retrospective cohort study. J Rural Health. 2023; doi:10.1111/jrh.12756.
- 48. Pana TA, Luben RN, Mamas MA, Potter JF, Wareham NJ, Khaw K-T, Myint PK. Long term prognostic impact of sex-specific longitudinal changes in blood pressure. The EPIC-Norfolk Prospective Population Cohort Study. Eur J Prev Cardiol. 2022; 29:180-191. doi:10.1093/eurjpc/zwab104.
- 49. Zhao M, Woodward M, Vaartjes I, Millett ER, Klipstein-Grobusch K, Hyun K, Carcel C, Peters SA. Sex differences in cardiovascular medication prescription in primary care: a systematic review and metaanalysis. Journal of the American Heart Association. 2020; 9:e014742. doi.
- 50. Wenger NK, Arnold A, Bairey Merz CN, Cooper-DeHoff RM, Ferdinand KC, Fleg JL, Gulati M, Isiadinso I, Itchhaporia D, Light-McGroary K. Hypertension across a woman's life cycle. Journal of the American College of Cardiology. 2018; 71:1797-1813. doi.
- 51. Stone NJ, Smith Jr SC, Orringer CE, Rigotti NA, Navar AM, Khan SS, Jones DW, Goldberg R, Mora S, Blaha M. Managing atherosclerotic cardiovascular risk in young adults: JACC state-of-the-art review. J Am Coll Cardiol. 2022; 79:819-836. doi:10.1016/j.jacc.2021.12.016.
- 52. Wang J, Jiang W, Sharma M, Wu Y, Li J, You N, Ding Z, Zhao X, Chen H, Tang H. Sex differences in antihypertensive drug use and blood pressure control. Postgrad Med J. 2019; 95:295-299. doi:10.1136/postgradmedj-2019-136513.